Novo Nordisk Reports Semaglutide Blockbuster Sales of $21.2 Billion in 2023, with Wegovy Surging 407%

In terms of products, the sales of Ozempic, the injectable version of semaglutide for glycemic control, reached $13.89 billion, representing a 60% year-over-year increase; the sales of oral glycemic control drug Rybelsus amounted to $2.72 billion, marking a 66% year-over-year growth, and this product has just been approved for marketing in China; the sales of Wegovy, the weight management version, were $4.548 billion, surging by 407% year-over-year. The combined sales of the three semaglutide products totaled $21.157 billion. Additionally, the sales of Victoza (liraglutide) were $1.257 billion, reflecting a 30% year-over-year decline, while the sales of Saxenda for weight management were $1.493 billion, showing a 4% year-over-year decrease. The total revenue from Novo Nordisk's GLP-1 class products was $23.9 billion, accounting for 70% of the company’s total revenue.

Summary